The key catalyst is the November 28, 2026 PDUFA date for D-PLEX₁₀₀; the Investor Day may provide pipeline color but is unlikely to move the stock materially unless unexpected clinical or regulatory updates are revealed. Monitor the event for any changes to D-PLEX₁₀₀ approval probability or PD01B development timeline.
Price Chart
Executive Summary
PolyPid announced a virtual Investor Day on October 28, 2026, to unveil its 'PolyPid 2030' long-term strategy and pipeline, including an update on D-PLEX₁₀₀ (NDA under FDA Priority Review with a PDUFA date of November 28, 2026) and the introduction of a new candidate, PD01B, for diabetic foot infections. The event features a KOL discussion on diabetic foot infections, but no financial data, guidance, or material business changes were disclosed. This is a forward-looking pipeline and strategy event with no immediate financial impact.
Key Facts
- Virtual Investor Day scheduled for October 28, 2026, at 11:30 a.m. ET.
- Company to outline 'PolyPid 2030' long-term growth and pipeline strategy.
- D-PLEX₁₀₀ NDA is under FDA Priority Review with a PDUFA goal date of November 28, 2026.
- New product candidate PD01B introduced for diabetic foot infections, based on Kynatrix delivery technology.
- KOL Warren S. Joseph, DPM, FIDSA, will discuss diabetic foot infections and controlled-release antibiotic therapy.
- No financial results, guidance, or material agreements were announced.
Financial Impact
No financial figures disclosed; event is strategic and forward-looking.
Risk Factors
- FDA may not approve D-PLEX₁₀₀ by the PDUFA date or may issue a Complete Response Letter.
- PD01B is preclinical/early-stage and faces significant development and regulatory risks.
- No revenue or near-term cash flow; company is pre-commercial and dependent on financing.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3381628 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | Press Release | $4.90 | awaiting T+60 | — | $5.77 (+17.76%) |
Oct 1, 2026 26d ago | 6-K | $5.37 | awaiting T+60 | — | $5.77 (+7.45%) |
Oct 1, 2026 26d ago | Press Release | $5.37 | awaiting T+60 | — | $5.77 (+7.45%) |
Oct 1, 2026 26d ago | 6-K | $5.37 | awaiting T+60 | — | $5.77 (+7.45%) |
Oct 1, 2026 26d ago | Press Release | $5.37 | awaiting T+60 | — | $5.77 (+7.45%) |
Aug 12, 2026 10w ago | 6-K | $4.78 | awaiting T+60 | — | $5.77 (+20.71%) |
Aug 12, 2026 10w ago | 6-K | $4.84 | awaiting T+60 | — | $5.77 (+19.21%) |
Aug 12, 2026 10w ago | Press Release | $4.84 | awaiting T+60 | — | $5.77 (+19.21%) |
Jul 29, 2026 12w ago | 6-K | $4.08 $5.13 | ▲ +25.74% | ▲ +21.01% | $5.77 (+41.42%) |
Jul 21, 2026 14w ago | 6-K | $3.74 $4.83 | ▲ +29.14% | ▲ +26.30% | $5.77 (+54.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers